A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)

V. Lee, M. Zahurak, A. Cercek, H. Verheul, H. Lenz, P. Jones, S. Baylin, R. Parkinson, V. Rami, E. Lilly, T. Miles, T. Brown, N. Ahuja, A. El Khoueiry, N. Azad

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)S12
JournalEuropean Journal of Cancer
Publication statusPublished - Oct 2020

Cite this